Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens

Antimicrob Agents Chemother. 2001 May;45(5):1547-9. doi: 10.1128/AAC.45.5.1547-1549.2001.

Abstract

Ingestion of thalidomide was associated with a reduction in the upregulation of the granulocyte activation marker CD11b and a reduced capacity to release elastase and lactoferrin after stimulation with lipopolysaccharide or lipoteichoic acid. A single oral dose of thalidomide attenuates neutrophil activation upon ex vivo stimulation with bacterial antigens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Antigens, Bacterial / pharmacology*
  • Drug Interactions
  • Granulocytes / drug effects*
  • Granulocytes / metabolism
  • Humans
  • Lactoferrin / metabolism
  • Lipopolysaccharides / pharmacology
  • Macrophage-1 Antigen / metabolism*
  • Neutrophil Activation / drug effects*
  • Pancreatic Elastase / metabolism
  • Thalidomide / pharmacology*

Substances

  • Anti-Inflammatory Agents
  • Antigens, Bacterial
  • Lipopolysaccharides
  • Macrophage-1 Antigen
  • Thalidomide
  • Lactoferrin
  • Pancreatic Elastase